Operaciones BridgeBio Pharma, Inc. - BBIO CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.06 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
BridgeBio Pharma Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 13.51 |
| Abrir* | 13.35 |
| Cambio de 1 año* | 102.58% |
| Rango del día* | 13.32 - 13.74 |
| Rango de 52 semanas | 5.74-19.95 |
| Volumen medio (10 días) | 1.48M |
| Volumen medio (3 meses) | 67.24M |
| Capitalización de mercado | 2.21B |
| Ratio P/E | -100.00K |
| Acciones en circulación | 160.50M |
| Ingresos | 77.78M |
| EPS | -2.83 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.70 |
| Próxima fecha de resultados | Aug 2, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 13.73 | 0.66 | 5.05% | 13.07 | 13.78 | 13.02 |
| May 25, 2023 | 13.51 | 0.23 | 1.73% | 13.28 | 13.60 | 12.72 |
| May 24, 2023 | 13.26 | -0.32 | -2.36% | 13.58 | 13.60 | 12.98 |
| May 23, 2023 | 13.61 | -0.07 | -0.51% | 13.68 | 14.38 | 13.51 |
| May 22, 2023 | 13.67 | -0.06 | -0.44% | 13.73 | 13.99 | 13.59 |
| May 19, 2023 | 13.68 | -0.29 | -2.08% | 13.97 | 14.38 | 13.64 |
| May 18, 2023 | 13.94 | 0.10 | 0.72% | 13.84 | 14.02 | 13.48 |
| May 17, 2023 | 14.04 | 0.10 | 0.72% | 13.94 | 14.18 | 13.78 |
| May 16, 2023 | 14.06 | -0.36 | -2.50% | 14.42 | 14.45 | 13.90 |
| May 15, 2023 | 14.80 | 1.28 | 9.47% | 13.52 | 14.92 | 13.44 |
| May 12, 2023 | 13.51 | -0.71 | -4.99% | 14.22 | 14.25 | 13.48 |
| May 11, 2023 | 14.23 | 0.42 | 3.04% | 13.81 | 14.40 | 13.70 |
| May 10, 2023 | 13.78 | -0.06 | -0.43% | 13.84 | 14.04 | 13.38 |
| May 9, 2023 | 13.72 | 0.47 | 3.55% | 13.25 | 14.01 | 13.03 |
| May 8, 2023 | 13.47 | -0.61 | -4.33% | 14.08 | 14.08 | 13.43 |
| May 5, 2023 | 13.64 | 0.53 | 4.04% | 13.11 | 13.71 | 12.98 |
| May 4, 2023 | 13.45 | -0.71 | -5.01% | 14.16 | 14.34 | 13.19 |
| May 3, 2023 | 14.36 | 0.53 | 3.83% | 13.83 | 14.59 | 13.61 |
| May 2, 2023 | 13.92 | -0.31 | -2.18% | 14.23 | 14.23 | 13.48 |
| May 1, 2023 | 14.30 | 0.00 | 0.00% | 14.30 | 14.95 | 14.20 |
BridgeBio Pharma, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, June 21, 2023 | ||
| Hora (UTC) (UTC) 16:00 | País US
| Evento BridgeBio Pharma Inc Annual Shareholders Meeting BridgeBio Pharma Inc Annual Shareholders MeetingForecast -Previous - |
| Thursday, June 22, 2023 | ||
| Hora (UTC) (UTC) 16:00 | País US
| Evento BridgeBio Pharma Inc Annual Shareholders Meeting BridgeBio Pharma Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Hora (UTC) (UTC) 12:30 | País US
| Evento Q2 2023 BridgeBio Pharma Inc Earnings Release Q2 2023 BridgeBio Pharma Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Hora (UTC) (UTC) 12:30 | País US
| Evento Q3 2023 BridgeBio Pharma Inc Earnings Release Q3 2023 BridgeBio Pharma Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 77.648 | 69.716 | 8.249 | 40.56 | 0 |
| Ingresos | 77.648 | 69.716 | 8.249 | 40.56 | 0 |
| Coste de los ingresos, total | 3.434 | 3.114 | 0 | 2.5 | 0 |
| Beneficio bruto | 74.214 | 66.602 | 8.249 | 38.06 | 0 |
| Gastos totales de explotación | 589.85 | 646.348 | 482.731 | 307.216 | 164.333 |
| Gastos de venta/general/administración Gastos, total | 143.189 | 192.21 | 145.684 | 94.353 | 43.587 |
| Investigación y desarrollo | 399.462 | 451.024 | 337.047 | 207.947 | 140.073 |
| Gastos (ingresos) extraordinarios | 43.765 | 2.416 | -19.327 | ||
| Ingresos de explotación | -512.202 | -576.632 | -474.482 | -266.656 | -164.333 |
| Ingresos por intereses (gastos), netos No operativos | 35.05 | -45.645 | -32.64 | -20.719 | -0.818 |
| Otros, netos | -7.5 | 35.823 | 1.634 | -1.21 | -4.3 |
| Ingresos netos antes de impuestos | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Ingresos netos después de impuestos | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Intereses menores | 3.469 | 23.915 | 56.764 | 27.998 | 38.702 |
| Beneficio neto antes de partidas extra. Elementos | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Ingresos netos | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Beneficio neto diluido | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Promedio ponderado de acciones diluidas | 147.473 | 144.357 | 117.995 | 105.099 | 115 |
| BPA diluido sin partidas extraordinarias | -3.26285 | -3.89687 | -3.80289 | -2.47944 | -1.13695 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| BPA normalizado diluido | -2.96609 | -3.89687 | -3.80289 | -2.45645 | -1.30501 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 1.826 | 1.87 | 0.338 | 73.746 | 1.694 |
| Ingresos | 1.826 | 1.87 | 0.338 | 73.746 | 1.694 |
| Gastos totales de explotación | 127.989 | 131.102 | 129.454 | 153.922 | 175.372 |
| Gastos de venta/general/administración Gastos, total | 31.108 | 31.862 | 31.188 | 36.426 | 43.713 |
| Investigación y desarrollo | 92.861 | 90.902 | 92.511 | 108.4 | 107.649 |
| Ingresos de explotación | -126.163 | -129.232 | -129.116 | -80.176 | -173.678 |
| Ingresos por intereses (gastos), netos No operativos | -15.004 | -15.898 | -17.408 | 88.433 | -20.077 |
| Otros, netos | -1.565 | 4.56 | 6.331 | -10.816 | -7.575 |
| Ingresos netos antes de impuestos | -142.732 | -140.57 | -140.193 | -2.559 | -201.33 |
| Ingresos netos después de impuestos | -142.732 | -140.57 | -140.193 | -2.559 | -201.33 |
| Intereses menores | 2.576 | 2.979 | 2.854 | -7.297 | 4.933 |
| Beneficio neto antes de partidas extra. Elementos | -140.156 | -137.591 | -137.339 | -9.856 | -196.397 |
| Ingresos netos | -140.156 | -137.591 | -137.339 | -9.856 | -196.397 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -140.156 | -137.591 | -137.339 | -9.856 | -196.397 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -140.156 | -137.591 | -137.339 | -9.856 | -196.397 |
| Beneficio neto diluido | -140.156 | -137.591 | -137.339 | -9.856 | -196.397 |
| Promedio ponderado de acciones diluidas | 152.646 | 149.365 | 147.938 | 146.685 | 145.882 |
| BPA diluido sin partidas extraordinarias | -0.91818 | -0.92117 | -0.92836 | -0.06719 | -1.34627 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.89611 | -0.86968 | -0.89445 | -0.00995 | -1.19093 |
| Coste de los ingresos, total | 0.651 | 0.647 | 0.739 | 0.7 | 1.348 |
| Beneficio bruto | 1.175 | 1.223 | -0.401 | 73.046 | 0.346 |
| Gastos (ingresos) extraordinarios | 3.369 | 7.691 | 5.016 | 8.396 | 22.662 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 548.853 | 888.858 | 642.824 | 568.622 | 445.223 |
| Efectivo e inversiones a corto plazo | 471.922 | 836.663 | 607.093 | 545.993 | 436.086 |
| Efectivo y Equivalentes | 376.689 | 393.772 | 356.082 | 363.773 | 436.086 |
| Prepaid Expenses | 21.922 | 32.269 | 35.592 | 22.629 | 7.087 |
| Other Current Assets, Total | 55.009 | 19.926 | 0.139 | 2.05 | |
| Total Assets | 623.036 | 1012.79 | 703.588 | 631.679 | 464.941 |
| Property/Plant/Equipment, Total - Net | 25.247 | 45.973 | 36.833 | 5.625 | 1.575 |
| Property/Plant/Equipment, Total - Gross | 1.806 | ||||
| Accumulated Depreciation, Total | -0.231 | ||||
| Long Term Investments | 31.144 | 17.05 | |||
| Other Long Term Assets, Total | 20.224 | 33.027 | 23.931 | 26.288 | 1.093 |
| Total Current Liabilities | 121.428 | 135.069 | 95.648 | 60.385 | 32.577 |
| Accounts Payable | 11.558 | 11.884 | 8.945 | 8.852 | 13.509 |
| Accrued Expenses | 101.714 | 122.89 | 79.567 | 47.455 | 15.062 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 8.156 | 0 | 5.55 | 4.078 | 4.006 |
| Total Liabilities | 1877.65 | 1883.21 | 645.682 | 223.225 | 150.062 |
| Total Long Term Debt | 1707.61 | 1705.05 | 477.43 | 91.791 | 54.507 |
| Long Term Debt | 1707.61 | 1703.81 | 475.857 | 91.791 | 54.507 |
| Minority Interest | 9.693 | 4.835 | 49.98 | 67.522 | 62.483 |
| Other Liabilities, Total | 38.917 | 38.252 | 22.624 | 3.527 | 0.495 |
| Total Equity | -1254.62 | -870.414 | 57.906 | 408.454 | 314.879 |
| Preferred Stock - Non Redeemable, Net | 478.865 | ||||
| Common Stock | 0.157 | 0.154 | 0.125 | 0.124 | 3.373 |
| Retained Earnings (Accumulated Deficit) | -1918.15 | -1436.97 | -888.755 | -440.031 | -167.359 |
| Total Liabilities & Shareholders’ Equity | 623.036 | 1012.79 | 703.588 | 631.679 | 464.941 |
| Total Common Shares Outstanding | 150.626 | 147.343 | 122.849 | 123.658 | 115 |
| Inversiones a corto plazo | 95.233 | 442.891 | 251.011 | 182.22 | |
| Redeemable Preferred Stock | 0 | ||||
| Additional Paid-In Capital | 938.703 | 841.53 | 1021.34 | 848.107 | |
| Other Equity, Total | -0.328 | -0.132 | 0.192 | 0.254 | |
| Current Port. of LT Debt/Capital Leases | 0.295 | 1.586 | |||
| Capital Lease Obligations | 1.245 | 1.573 | |||
| Treasury Stock - Common | -275 | -275 | -75 | ||
| Intangibles, Net | 28.712 | 44.934 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 552.702 | 548.853 | 642.219 | 771.28 | 716.23 |
| Efectivo e inversiones a corto plazo | 491.293 | 471.922 | 591.977 | 715.705 | 671.226 |
| Efectivo y Equivalentes | 407.368 | 376.689 | 483.235 | 470.098 | 371.55 |
| Inversiones a corto plazo | 83.925 | 95.233 | 108.742 | 245.607 | 299.676 |
| Total deudores, neto | |||||
| Prepaid Expenses | 25.145 | 21.922 | 25.521 | 32.614 | 33.844 |
| Total Assets | 625.68 | 623.036 | 728.74 | 862.233 | 813.149 |
| Property/Plant/Equipment, Total - Net | 24.098 | 25.247 | 27.341 | 29.723 | 31.118 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 20.767 | 20.224 | 29.87 | 31.322 | 35.325 |
| Total Current Liabilities | 96.596 | 121.428 | 119.194 | 141.16 | 103.463 |
| Accounts Payable | 4.076 | 11.558 | 10.158 | 8.793 | 10.107 |
| Accrued Expenses | 85.845 | 101.714 | 101.518 | 125.177 | 93.356 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 6.675 | 8.156 | 7.518 | 7.19 | |
| Total Liabilities | 1851.34 | 1877.65 | 1867.16 | 1887.77 | 1854.15 |
| Total Long Term Debt | 1713.29 | 1707.61 | 1698.69 | 1693.18 | 1708.05 |
| Long Term Debt | 1713.29 | 1707.61 | 1698.69 | 1693.18 | 1708.05 |
| Capital Lease Obligations | |||||
| Minority Interest | 12.052 | 9.693 | 8.044 | 10.519 | 0.309 |
| Other Liabilities, Total | 29.405 | 38.917 | 41.226 | 42.907 | 42.323 |
| Total Equity | -1225.67 | -1254.62 | -1138.42 | -1025.53 | -1041 |
| Common Stock | 0.167 | 0.157 | 0.156 | 0.154 | 0.154 |
| Additional Paid-In Capital | 1106.64 | 938.703 | 917.333 | 892.96 | 867.596 |
| Retained Earnings (Accumulated Deficit) | -2057.46 | -1918.15 | -1780.56 | -1643.22 | -1633.36 |
| Treasury Stock - Common | -275 | -275 | -275 | -275 | -275 |
| Other Equity, Total | -0.012 | -0.328 | -0.348 | -0.427 | -0.383 |
| Total Liabilities & Shareholders’ Equity | 625.68 | 623.036 | 728.74 | 862.233 | 813.149 |
| Total Common Shares Outstanding | 160.435 | 150.626 | 149.367 | 148.246 | 147.694 |
| Accounts Receivable - Trade, Net | |||||
| Other Current Assets, Total | 36.264 | 55.009 | 24.721 | 22.961 | 11.16 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Intangibles, Net | 28.113 | 28.712 | 29.31 | 29.908 | 30.476 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Efectivo de actividades de explotación | -419.494 | -497.934 | -399.714 | -253.587 | -136.643 |
| Efectivo de actividades de explotación | 6.771 | 5.843 | 0.245 | ||
| Partidas no monetarias | 24.047 | 83.736 | 90.84 | 45.913 | 10.072 |
| Intereses pagados en efectivo | 54.443 | 29.774 | 15.322 | 6.092 | 1.574 |
| Cambios en el capital circulante | 34.34 | -1.059 | 14.934 | -10.915 | 22.491 |
| Efectivo de actividades de inversión | 453.147 | -200.826 | -52.993 | -217.253 | -21.036 |
| Gastos de capital | -6.321 | -13.246 | -7.518 | -5.138 | -18.178 |
| Otras partidas de flujo de caja de inversión, total | 459.468 | -187.58 | -45.475 | -212.115 | -2.858 |
| Efectivo procedente de actividades de financiación | -13.134 | 736.446 | 447.189 | 398.792 | 501.548 |
| Elementos de flujo de caja de financiación | -0.724 | -163.695 | -41.939 | -7.272 | 14.196 |
| Emisión (retiro) de acciones, neto | 8.076 | -179.536 | -60.872 | 368.946 | 430.974 |
| Emisión (amortización) de deuda, neta | -20.486 | 1079.68 | 550 | 37.118 | 56.378 |
| Variación neta de la tesorería | 20.519 | 37.686 | -5.518 | -72.048 | 343.869 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -142.732 | -484.652 | -344.082 | -203.889 | -201.33 |
| Cash From Operating Activities | -144.322 | -419.494 | -326.251 | -191.088 | -160.635 |
| Non-Cash Items | 28.579 | 24.047 | -9.872 | -20.128 | 42.625 |
| Cash Interest Paid | 22.059 | 54.443 | 47.575 | 25.435 | 18.809 |
| Changes in Working Capital | -31.802 | 34.34 | 22.592 | 29.463 | -3.814 |
| Cash From Investing Activities | 12.298 | 453.147 | 435.182 | 288.325 | 138.623 |
| Capital Expenditures | -0.012 | -6.321 | -5.52 | -4.761 | -0.859 |
| Other Investing Cash Flow Items, Total | 12.31 | 459.468 | 440.702 | 293.086 | 139.482 |
| Cash From Financing Activities | 150.249 | -13.134 | -19.511 | -20.956 | -0.16 |
| Financing Cash Flow Items | 5.231 | -0.724 | -2.192 | -1.596 | -1.23 |
| Issuance (Retirement) of Stock, Net | 145.018 | 8.076 | 3.167 | 1.126 | 1.07 |
| Issuance (Retirement) of Debt, Net | -20.486 | -20.486 | -20.486 | 0 | |
| Net Change in Cash | 18.225 | 20.519 | 89.42 | 76.281 | -22.172 |
| Cash From Operating Activities | 1.633 | 6.771 | 5.111 | 3.466 | 1.884 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | Private Equity | 19.3525 | 31060971 | 0 | 2023-03-31 | MED |
| Viking Global Investors LP | Investment Advisor/Hedge Fund | 16.5862 | 26620991 | 0 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.5093 | 12052540 | 1471801 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.6814 | 7513663 | -213232 | 2023-03-31 | LOW |
| Kumar (Neil) | Individual Investor | 4.3997 | 7061605 | 0 | 2023-05-17 | LOW |
| Aisling Capital Management LP | Investment Advisor/Hedge Fund | 3.7807 | 6068125 | 0 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.2043 | 5143013 | -3701930 | 2023-03-31 | LOW |
| Cormorant Asset Management, LP | Hedge Fund | 2.8395 | 4557414 | 3188235 | 2023-03-31 | LOW |
| HHLR Advisors, Ltd. | Investment Advisor/Hedge Fund | 2.4787 | 3978410 | -1208815 | 2023-03-31 | LOW |
| Laurion Capital Management LP | Hedge Fund | 2.1886 | 3512759 | 1289505 | 2023-03-31 | HIGH |
| SunAmerica Asset Management, LLC | Investment Advisor | 1.685 | 2704374 | -1015711 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4038 | 2253158 | 187251 | 2023-03-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.3907 | 2232021 | -468803 | 2023-03-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.311 | 2104234 | 1401129 | 2023-03-31 | LOW |
| Perceptive Advisors LLC | Private Equity | 1.1882 | 1907033 | 210000 | 2023-03-31 | MED |
| Sequoia Capital Global Equities | Venture Capital | 1.1591 | 1860364 | 0 | 2023-03-31 | LOW |
| Citi Investment Research (US) | Research Firm | 0.9639 | 1547045 | 162116 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.8987 | 1442432 | 901628 | 2023-03-31 | LOW |
| BofA Global Research (US) | Research Firm | 0.8505 | 1365057 | 519245 | 2023-03-31 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 0.8337 | 1338160 | 404417 | 2023-03-31 | MED |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group530K+
Traders
87K+
Clientes activos mensualmente
$46M+
Volumen mensual de inversión
$31M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
BridgeBio Pharma, Inc. Company profile
Sobre BridgeBio Pharma Inc
BridgeBio Pharma, Inc. es una empresa biofarmacéutica en fase comercial fundada para descubrir, crear, probar y suministrar medicamentos transformadores para tratar a los pacientes que padecen enfermedades genéticas y cánceres con claros impulsores genéticos. La empresa cuenta con aproximadamente 30 programas de desarrollo que van desde la ciencia inicial hasta los ensayos clínicos avanzados, y su organización comercial está centrada en el suministro de las dos primeras terapias aprobadas de la empresa y en la preparación del posible lanzamiento comercial de otras terapias. Los productos de la empresa incluyen BBP-265, BBP-831, BBP-631, Encaleret y KRAS. Su Acoramidis (AG10) está en fase III de ensayo clínico para el tratamiento de la amiloidosis-cardiomiopatía TTR (ATTR-CM). Su infigratinib a dosis bajas (BBP-831) está en fase II de ensayo clínico para el tratamiento de la acondroplasia en pacientes pediátricos. Su BBP-631 está en fase I/II de ensayo clínico para el tratamiento de la hiperplasia suprarrenal congénita (HSC).
El precio actual de la acción BridgeBio Pharma, Inc. en tiempo real es 13.72 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Viveve Medical, Inc., Greencore Group PLC, Getinge B, Manhattan Bridge, DBV Technologies SA y Empresas ICA, S.A.B. de C.V.. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biopharmaceuticals |
3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 530.000 traders de todo el mundo que eligen operar con Capital.com